Skip to main content
S.C.P.C logo

S.C.P.C — Investor Relations & Filings

Ticker · 1720 ISIN · TW0001720001 TW Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2025-04-09 Director's Dealing
Country TW Taiwan
Listing TW 1720

About S.C.P.C

http://www.standard.com.tw

Standard Chemical & Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical manufacturer established in 1967. The company specializes in the research, development, production, and marketing of a wide range of pharmaceutical products, including generic Western medicines, Active Pharmaceutical Ingredients (APIs), and healthcare supplements. Its therapeutic portfolio covers diverse areas such as cardiovascular, metabolic, respiratory, anti-infective, and musculoskeletal systems, as well as dermatological and urogenital treatments. As a prominent generic drug manufacturer, the company operates with an integrated business model that spans from high-tech R&D to brand management and distribution. Adhering to international quality standards and ISO 9001 certification, it focuses on technological innovation and sustainable growth to serve diverse healthcare needs across domestic and international markets.

Recent filings

Filing Released Lang Actions
114年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and senior management, showing their current and initial shareholdings, pledged shares, and related party holdings. It is a disclosure of insider shareholdings and changes, typical of a Director's Dealing or insider shareholding notification. There is no indication of financial results, management discussion, or report publication. The document length is short (2598 characters) and contains no financial statements or earnings data. The content matches the definition of Director's Dealing (DIRS) as it reports personal share transactions or holdings by company directors and executives.
2025-04-09 Chinese
114年3月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 生達, providing information on fund lending balances and endorsement guarantees for the current and previous month. It contains tabular data with monetary amounts but is very short (607 characters) and does not include comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure related to financing or guarantees rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement with financial data but not a full financial report or specific category like capital update or earnings release.
2025-04-09 Chinese
114年3月營業收入
Interim / Quarterly Report Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 生達, presented in a tabular format with explanations about accounting standards and reporting practices. It contains actual financial data for a specific month (March of year 114 in the Taiwanese calendar) and compares it to the previous year. The document length is short (770 characters), but it includes substantive financial data rather than just an announcement or a link to a report. It is not a full annual or interim report but rather a periodic financial summary. Given the presence of actual financial figures and the nature of the data, this fits best as an Interim / Quarterly Report (IR) rather than a simple earnings release or regulatory filing. The document is not a call transcript, audit report, or any other category. Therefore, the classification is IR with high confidence.
2025-04-09 Chinese
代子公司「江蘇生達生技醫藥有限公司」公告資金貸與 超限改善計畫
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (1720 生達) regarding a subsidiary's financial issue and an improvement plan related to excess fund lending limits. It references a directive from the Financial Supervisory Commission and details corrective actions including bankruptcy proceedings. The document is short (1036 characters) and serves as a disclosure of a material event affecting shareholder interests and securities price, but it does not contain financial statements or detailed financial reports. It is not an annual or interim report, nor a call transcript or earnings release. It fits best as a Regulatory Filing (RNS) because it is a compliance disclosure about a significant corporate event without detailed financial data or report format.
2025-04-02 Chinese
公告本公司董事會決議認購易威生醫科技股份有限公司私募普通股
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding a board resolution to subscribe to private shares of another company. It details the transaction specifics such as number of shares, price, total amount, relationship between parties, and board approval date. There is no financial report, earnings data, or management discussion. The content fits the category of Capital/Financing Update as it relates to a financing activity (private placement subscription). The document length is short and it is not an announcement of a report publication or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-03-25 Chinese
113年第4季海外子公司投資
Regulatory Filings Classification · 90% confidence The document is a financial table showing investment details in overseas subsidiaries, including shareholding percentages, original investment amounts, investment balances, and recognized investment gains or losses for the current period and prior year-end. The document is short (1190 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report. There is no indication of it being an annual or interim report, audit report, or earnings release. It does not contain management commentary or governance information. The content fits best as a Regulatory Filing (RNS) because it is a specific financial disclosure but not a comprehensive report or announcement of a report.
2025-03-18 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.